Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Transpek Industry Ltd (TRANSPEK) is currently trading at 1,038.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Transpek Industry Limited is a specialty chemical manufacturer focused on chlorinated products and acid chlorides, operating multiproduct plants in Vadodara with a stated aggregate capacity of 66,000 MTPA and a global export footprint across North America, Europe, South America and Eurasia, positioning itself as a leading Indian supplier for polymers, pharma and specialty chemistries. Recent financials show stable revenues with Q3 FY26 at ₹162.0 crore and 9M FY26 revenue of ₹493.2 crore, while profitability improved with 9M EBITDA rising 14.9% year‑on‑year to ₹95.9 crore and EBITDA margin expanding to c.19.4%, reflecting favourable product mix and cost management despite modest top‑line pressure versus prior periods. Transpek derives a high degree of international exposure (85%+ of Q3 revenues exported, ~68% to North America), relies heavily on polymer applications (68.5% of Q3 sales) and benefits from a decade‑long exclusive supply contract for acid chlorides with an MNC, which materially enhances revenue visibility and strategic positioning in key global supply chains. The company emphasizes R&D and sustainable operations: a DSIR‑recognised R&D lab, kilo and pilot plants accelerate commercialization of non‑acid and non‑alkyl chloride chemistries expected to scale in 2026–27; concurrent sustainability recognitions (EcoVadis Gold, Responsible Care) and logistics scale (600+ ISO tanks) differentiate Transpek on safety and customer service. Management is conservatively managing cash and capex decisions while targeting an average EBITDA band of 16–20% depending on product mix; strategic priorities are new product commercialization, measured geographic expansion into Eurasia and South America, and continued focus on sustainability and long‑term customer relationships to drive profitable growth.
Over the past 52 weeks, Transpek Industry Ltd has traded between a low of ₹864.00 and a high of ₹1,778.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Transpek Industry Ltd has a market capitalization of approximately 546.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Transpek Industry Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 546.02 Cr, Transpek Industry Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Transpek Industry Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Transpek Industry Ltd is 11.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discovery themes featuring this stock
Transpek Industry Limited is a specialty chemical manufacturer focused on chlorinated products and acid chlorides, operating multiproduct plants in Vadodara with a stated aggregate capacity of 66,000 MTPA and a global export footprint across North America, Europe, South America and Eurasia, positioning itself as a leading Indian supplier for polymers, pharma and specialty chemistries.
Recent financials show stable revenues with Q3 FY26 at ₹162.0 crore and 9M FY26 revenue of ₹493.2 crore, while profitability improved with 9M EBITDA rising 14.9% year‑on‑year to ₹95.9 crore and EBITDA margin expanding to c.19.4%, reflecting favourable product mix and cost management despite modest top‑line pressure versus prior periods.
Transpek derives a high degree of international exposure (85%+ of Q3 revenues exported, ~68% to North America), relies heavily on polymer applications (68.5% of Q3 sales) and benefits from a decade‑long exclusive supply contract for acid chlorides with an MNC, which materially enhances revenue visibility and strategic positioning in key global supply chains.
The company emphasizes R&D and sustainable operations: a DSIR‑recognised R&D lab, kilo and pilot plants accelerate commercialization of non‑acid and non‑alkyl chloride chemistries expected to scale in 2026–27; concurrent sustainability recognitions (EcoVadis Gold, Responsible Care) and logistics scale (600+ ISO tanks) differentiate Transpek on safety and customer service.
Management is conservatively managing cash and capex decisions while targeting an average EBITDA band of 16–20% depending on product mix; strategic priorities are new product commercialization, measured geographic expansion into Eurasia and South America, and continued focus on sustainability and long‑term customer relationships to drive profitable growth.
Chemicals & Petrochemicals
Commodity Chemicals
546 Cr
Moderate Risk
12.0
42.3
0.5
0.7
1,778.95
864.00
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
5
Neutral
5
Bullish
4
Bearish
26
Neutral
5
Bullish
15
Bearish
21
Neutral
0
Bullish
11
Investor Presentation
Transpek Industry Ltd released its June 2026 investor presentation reporting FY26 consolidated revenue of Rs.645.7 Cr, EBITDA Rs.117.9 Cr (18.3% margin), PAT Rs.45.6 Cr, EPS Rs.81.72 and a board‑recommended dividend of Rs.20/share.
Investor Presentation
Transpek released its June 2026 investor presentation reporting FY26 consolidated revenue Rs 645.7 Cr, EBITDA Rs 117.9 Cr, PAT Rs 45.6 Cr, recommended dividend of ₹20/share; noted YoY softening and cautious outlook.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
53.05 | 653 Cr | 17.82 | 3.61 | 0.00 | 20.25 | 13.95 | 5.90 | ||
128.40 | 611 Cr | 12.80 | 1.42 | 1.47 | 11.06 | 11.62 | 7.93 | ||
24.90 | 585 Cr | 38.07 | 1.57 | 0.00 | 3.78 | 6.57 | 1.52 | ||
193.00 | 578 Cr | 15.01 | 3.68 | 0.68 | 24.54 | 32.63 | 20.49 | ||
375.00 | 565 Cr | -164.77 | 1.51 | 0.32 | -0.91 | 1.49 | -0.59 | ||
1038.40 | 546 Cr | 11.96 | 0.71 | 2.05 | 5.95 | 8.23 | 4.53 | ||
165.00 | 499 Cr | 12.03 | 2.57 | 0.49 | 21.32 | 21.36 | 10.86 | ||
| Median: 7 Co. | — | 165.00 | 578 Cr | 12.80 | 1.57 | 0.49 | 11.06 | 11.62 | 5.90 |
